je.st
news
Home
› Cerenis Receives EMA Orphan Drug Designations For CER-001 For The Treatment Of ApoA-I And ABCA-1 Deficiencies
Cerenis Receives EMA Orphan Drug Designations For CER-001 For The Treatment Of ApoA-I And ABCA-1 Deficiencies
2014-09-03 12:18:47| drugdiscoveryonline Home Page
Cerenis Therapeutics, the biopharmaceutical company developing CER-001, an engineered human apoA-I-containing pre-beta HDL mimetic, for the treatment of cardiovascular disease, recently announced that it has received two separate Orphan Drug Designations from the European Medicines Agency (EMA) for the use of CER-001 in the treatment of patients with rare genetic defects in HDL synthesis/maturation pathways, specifically apoA-I deficiency and ABCA1 deficiency
Tags: treatment
drug
receives
deficiencies
Category:Biotechnology and Pharmaceuticals